IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9375458 B1

PDFFull Text
Date of Patent:
Jun. 28, 2016

Filed:

Oct. 25, 2012

Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor

Applicant:

The Penn State Research Foundation, University Park, PA (US);

Inventors:

Ian S. Zagon, Hummelstown, PA (US);

Patricia J. McLaughlin, Harrisburg, PA (US);

Jill P. Smith, Camp Hill, PA (US);

Assignee:

The Penn State Research Foundation, University Park, PA (US);

Attorney:

McKee, Voorhees & Sease, PLC

Primary Examiner:

Marcos Sznaidman

Int. Cl.
CPC ...
A01N 41/10 (2006.01); A61K 31/10 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); A61K 38/08 (2006.01); A61K 31/00 (2006.01); A61K 31/138 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/505 (2006.01); A61K 31/525 (2006.01); A61K 31/573 (2006.01); A61K 31/66 (2006.01); A61K 31/663 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 41/00 (2006.01); A61K 45/06 (2006.01); A61K 31/282 (2006.01); A61K 31/513 (2006.01); A61K 31/7068 (2006.01); A61K 51/00 (2006.01); A61N 5/10 (2006.01); A61K 38/33 (2006.01);
U.S. Cl.
CPC ...
A61K 38/08 (2013.01); A61K 31/00 (2013.01); A61K 31/138 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/525 (2013.01); A61K 31/573 (2013.01); A61K 31/66 (2013.01); A61K 31/663 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 38/33 (2013.01); A61K 41/00 (2013.01); A61K 45/06 (2013.01); A61K 51/00 (2013.01); A61N 5/10 (2013.01);
Abstract

The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

Find Patent Forward Citations

Loading…